Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC

Millennium Management LLC increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 71.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,839 shares of the biopharmaceutical company's stock after acquiring an additional 80,140 shares during the quarter. Millennium Management LLC owned about 0.39% of Theravance Biopharma worth $1,815,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TBPH. Dimensional Fund Advisors LP raised its stake in Theravance Biopharma by 20.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after acquiring an additional 95,304 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in Theravance Biopharma by 9.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock worth $7,847,000 after acquiring an additional 69,178 shares in the last quarter. Trexquant Investment LP raised its stake in Theravance Biopharma by 50.7% during the 4th quarter. Trexquant Investment LP now owns 151,083 shares of the biopharmaceutical company's stock worth $1,422,000 after acquiring an additional 50,826 shares in the last quarter. Corton Capital Inc. acquired a new stake in Theravance Biopharma during the 4th quarter worth $314,000. Finally, Deutsche Bank AG increased its stake in Theravance Biopharma by 50.4% in the fourth quarter. Deutsche Bank AG now owns 46,550 shares of the biopharmaceutical company's stock valued at $438,000 after purchasing an additional 15,608 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on TBPH. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $11.33.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 370,038 shares of the company's stock, valued at approximately $3,330,342. The trade was a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by insiders.

Theravance Biopharma Trading Down 1.0%

Shares of NASDAQ:TBPH traded down $0.11 during midday trading on Wednesday, hitting $11.01. The stock had a trading volume of 318,294 shares, compared to its average volume of 276,675. The company has a market capitalization of $550.51 million, a PE ratio of -10.90 and a beta of -0.10. The stock has a 50 day moving average price of $9.23 and a two-hundred day moving average price of $9.37. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to analysts' expectations of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, equities analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.